Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 55.45
-2.11 (-3.67%)
At close: Apr 9, 2026
SHA:688192 Revenue
In the year 2025, Dizal (Jiangsu) Pharmaceutical had annual revenue of 801.14M CNY with 122.60% growth. Dizal (Jiangsu) Pharmaceutical had revenue of 214.83M in the quarter ending December 31, 2025, with 901.58% growth.
Revenue
801.14M
Revenue Growth
+122.60%
P/S Ratio
32.16
Revenue / Employee
940.30K
Employees
985
Market Cap
25.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 801.14M | 441.23M | 122.60% |
| Dec 31, 2024 | 359.90M | 268.61M | 294.24% |
| Dec 31, 2023 | 91.29M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 10.29M | -17.48M | -62.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Humanwell Healthcare (Group) | 23.96B |
| Livzon Pharmaceutical Group | 12.02B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Tasly Pharmaceutical Group | 8.24B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.02B |
| Shijiazhuang Yiling Pharmaceutical | 6.01B |
| Kangmei Pharmaceutical | 5.28B |